Discover published sets by community

Drug Class: Monoclonal Antibody Mechanism: Binds to IL-5, reducing the production and survival of eosinophils, which are implicated in certain types of asthma

Drug Class: Inhaled Corticosteroid Mechanism: Prevents the release of substances in the body that cause inflammation

Drug Class: Oral Corticosteroid Mechanism: Suppresses inflammation and the normal immune response

Drug Class: Long-acting Muscarinic Antagonist Mechanism: Causes bronchodilation by blocking muscarinic receptors in airway smooth muscles

Drug Class: Inhaled Corticosteroid Mechanism: Prodrug that is activated in the lungs to a metabolite with anti-inflammatory activity

Drug Class: Short-acting Beta-2 Agonist Mechanism: Stimulates beta-2 receptors resulting in smooth muscle relaxation in the airways

Drug Class: Long-acting Beta-2 Agonist Mechanism: Activates beta-2 receptors causing bronchial smooth muscle relaxation

Drug Class: Leukotriene Receptor Antagonist Mechanism: Blocks leukotriene receptors to reduce airway edema, smooth muscle contraction, and inflammation

Drug Class: Inhaled Corticosteroid Mechanism: Reduces inflammation and immune response in the airways

Drug Class: Inhaled Corticosteroid Mechanism: Anti-inflammatory properties reduce bronchial hyperresponsiveness

Drug Class: Leukotriene Synthesis Inhibitor Mechanism: Blocks 5-lipoxygenase enzyme necessary for the formation of leukotrienes

Drug Class: Plasma Kallikrein Inhibitor Mechanism: Inhibits plasma kallikrein and prevents bradykinin production, decreasing inflammation and capillary leakage

Drug Class: Inhaled Corticosteroid Mechanism: Anti-inflammatory effect by decreasing the production of inflammatory mediators

Drug Class: Long-acting Beta-2 Agonist Mechanism: Binds selectively to beta-2 receptors leading to bronchial smooth muscle relaxation

Drug Class: Short-acting Muscarinic Antagonist Mechanism: Inhibits acetylcholine on bronchial smooth muscle, leading to bronchodilation

Drug Class: Monoclonal Antibody Mechanism: Binds to IgE antibodies, preventing them from attaching to allergens and triggering the allergic response

Drug Class: Long-acting Muscarinic Antagonist Mechanism: Blocks acetylcholine-induced bronchoconstriction by antagonizing muscarinic receptors

Drug Class: Ultra-long-acting Beta-2 Agonist Mechanism: Provides bronchodilation by beta-2 receptor activation over 24 hours

Drug Class: Methylxanthine Mechanism: Nonselective phosphodiesterase inhibitor, increasing cAMP and leading to bronchodilation